Ojo A O, Port F K, Mauger E A, Wolfe R A, Leichtman A B
Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, USA.
Am J Kidney Dis. 1995 Apr;25(4):623-8. doi: 10.1016/0272-6386(95)90134-5.
Renal allograft survival of organs from living-related donors (LRDs) is superior to that of organs from cadaveric donors (CAD). Allograft survival rates are lower in black recipients of both CAD and LRD transplants compared with recipients of other races. It is not known whether the superior donor effect of LRD varies between races. We investigated the graft survival outcome of first renal transplants performed in the United States in 1986 and 1989 to determine whether the donor effect differs between black and white recipients. A measurement of "donor type effect" is introduced. There were 7,002 and 7,307 first renal transplants in 1986 and 1989, respectively, for which allograft survival data were available from the United States Renal Data Systems. Both black and white recipients showed a greater than 50% reduction in the risk of allograft loss at all the points studied up to 5 years posttransplant when LRD was chosen over CAD transplantation. A measurement of donor type effect indicates that graft loss is reduced by 7 to 21 percentage points at 1 and 5 years posttransplant. The donor type effect is proportionally equal in both races. Therefore, kidney donation from living relatives as a first transplant should be encouraged for all medically suitable end-stage renal disease patients as a means of improving outcome and reducing CAD transplantation waiting time for patients in whom LRD transplants cannot be performed.
来自活体亲属供者(LRD)的肾脏移植器官的存活情况优于尸体供者(CAD)的器官。与其他种族的受者相比,CAD和LRD移植的黑人受者的移植器官存活率较低。尚不清楚LRD的优越供者效应在不同种族之间是否存在差异。我们调查了1986年和1989年在美国进行的首次肾移植的移植存活结果,以确定黑人与白人受者之间的供者效应是否不同。引入了“供者类型效应”的衡量指标。1986年和1989年分别有7002例和7307例首次肾移植,其移植器官存活数据可从美国肾脏数据系统获得。当选择LRD移植而非CAD移植时,在移植后长达5年的所有研究时间点,黑人和白人受者的移植器官丢失风险均降低了50%以上。供者类型效应的衡量指标表明,移植后1年和5年时移植器官丢失率降低了7至21个百分点。两个种族的供者类型效应在比例上是相等的。因此,对于所有医学上适合的终末期肾病患者,应鼓励亲属活体供肾作为首次移植,以改善移植结果,并减少无法进行LRD移植的患者等待CAD移植的时间。